Cerba Healthcare, a medical diagnosis provider, agreed to acquire Viroclinics-DDL, a fast-growing global virology and immunology contract research organization, from Summit Partners, a private equity firm. Financial terms were not disclosed. "With Cerba Research, we have a new foundation for further global expansion to North America, Asia, and Africa with unrivalled expertise, capacity and capabilities. Together, we will be able to offer integrated solutions to the life science industry, accelerating antiviral, vaccine, and other R&D programs, while offering unmatched logistics solutions securing the integrity of fragile samples. Our 390+ scientists and experts look forward to joining Cerba Research in our continuous quest to provide the best possible science and service to our customers," Davide Molho, Viroclinics-DDL CEO.